NephroGenex — Investor Presentation (September 2015)
31 slides from NephroGenex's investor presentation, Sep 2, 2015
Slide 1: Corporate Presentation September 2015
Corporate Presentation September 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: NephroGenex Investment Thesis
NephroGenex Investment Thesis 3 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease Oral Pyridorin – for the prevention or slowing the progression of diabetic nephropa
Slide 4: NephroGenex Team
NephroGenex Team Member Previous Affiliations/Positions Pierre Legault, Chief Executive Officer Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Iroko, Tobira, Cyclacel, Forest Labs, others Dr. Jai Patel, M
Slide 5: NephroGenex Pipeline
NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop
Slide 6: Oral Pyridorin – Significant Market Potential
Oral Pyridorin – Significant Market Potential 6 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 32 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U
Slide 7: Pathophysiology of Diabetic Complications
7 Pathophysiology of Diabetic Complications
Slide 8: Pyridorin – Mechanism of Action
8 Pyridorin – Mechanism of Action
Slide 9: Preclinical: Pyridoxamine in STZ-Treated Rat Model of Type 1 DN
9 Preclinical: Pyridoxamine in STZ-Treated Rat Model of Type 1 DN Control rats +/– pyridoxamine Untreated diabetic rats diabetic rats + aminoguanidine diabetic rats + pyridoxamine Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Degenhardt et al. Kidney
Slide 10: Pyridorin Development Program
10 Pyridorin Development Program Target Indication: Prevention or slowing the progression of diabetic nephropathy with type 2 diabetes Program: Two identical, double-blind Phase 3 studies of 600 patients each Regulatory Agreements: FDA Special Protocol Assessment New endpoint of 50% increase in seru
Slide 11: Overview of Phase 3 Study - PIONEER
Objective: Evaluate safety and efficacy of Pyridorin at a 300mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population: Type 2 diabetic patients Baseline SCr greater than 1.3 and less than 3.0mg/dL (eGFR > 20 ml/min) an
Slide 12: Phase 2 Clinical Data Supporting Phase 3 Program
12 Phase 2 Clinical Data Supporting Phase 3 Program Based on data from 650+ patients in Phase 2 studies, the NephroGenex team was able to: Identify the target population – Type 2 diabetics Identify the relevant sub-group – elevated SCr, overt proteinuria on stable SOC Select the dose for Phase 3 – 3
Slide 13: Ph2 Data Supporting Patient Selection for Ph3
13 Ph2 Data Supporting Patient Selection for Ph 3 (Type 2 Diabetes; SCr 1.3-3mg/dL; Urinary Protein >1200mg/g Cr; Stable SOC) *Post-hoc analysis PYR-206* (26 week study) PYR-205/205 (26 week study) PYR-210* (52 week study)
Slide 14: Population in Phase 3 (PYR-210 Phase 2b Study)
2 2.1 2.2 2.3 2.4 2.5 0 4 12 26 39 52 SOC Placebo SOC 300 mg 14 Population in Phase 3 Agreed with FDA via the Special Protocol Assessment Weeks Mean SCr (mg/dL) PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients and SCr <3mg/dL
Slide 15: PIONEER Phase 3 Interim Analysis
PIONEER Phase 3 Interim Analysis 15 DSMB: Monitoring unblinded safety information on an ongoing basis Interim Analysis 1* (mid-2016): Independent biostatistician will undertake an interim analysis when at least 150 patients have completed a minimum of 12 months on treatment Interim Analysis 2* (summ
Slide 16: NephroGenex Phase 1 & 2 Safety Trials
Pyridorin was well tolerated in Phase 1 & 2 trials with a safety profile comparable to placebo: No maximum dose tolerability found in animals and healthy humans No significant differences between groups in SAEs or mortality No differences between groups for laboratory parameters (hematology, chemist
Slide 17: Promising early results for intravenous Pyridorin
Promising early results for intravenous Pyridorin An increase in oxidative and carbonyl stress has been implicated in the pathogenesis of acute kidney injury seen with ischemia reperfusion injury Pyridorin targets the increased oxidative and carbonyl stress associated with acute kidney Pyridorin tre
Slide 18: Exclusivity Patents and New Chemical Entity (NCE)
No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S. Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension) Method of manufacture patent February 2025 NCE - 5 year exclusivity
Slide 19: NephroGenex Milestones
NephroGenex Milestones 19 Achieved Expected Feb-2014 Completion of Initial Public Offering Mar-2014 Secured CRO June-2014 Enrolled first patient in PIONEER pivotal Phase 3 trial Nov-2014 Publication on new endpoint Nov-2014 Poster presentations at American Society of Nephrology Dec-2014 Successful c
Slide 20: Financial Snapshot
Financial Snapshot Cash As of June 30, 2015, approximately $18.9 million in cash, cash equivalents and investments Raised an additional $8.1 million of gross proceeds from a public offering in July 2015 Sufficient cash balance to finance operations into early 2016 NASDAQ: NRX (as of August 31, 2015)
Slide 21: Corporate Summary
Corporate Summary 21 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease Oral Pyridorin – for the prevention or slowing the progression of diabetic nephropathy in pati
Slide 22: NephroGenex
) NephroGenex
Slide 23: PYR-206 Phase 2a Study (50mg BID)
23 PYR-206 – 24 Week Phase 2a Study (50mg BID) PYR-206 Multi-center, randomized, double-blind, placebo-controlled trial to assess safety, tolerability and biological activity: N = 128 Population: Type 1 or type 2 diabetes Baseline SCr < 2.0mg/dL Urinary Protein: Creatinine Ratio (PCR) >300mg/gm Endp
Slide 24: PYR-205/207 Phase 2a Study (250mg BID)
24 PYR-205/207 – 24 Week Phase 2a Study (250mg BID) PYR-205/207 Multi-center, randomized, double-blind, dose-escalating, placebo-controlled trial to assess safety, tolerability and biological activity: N = 84 Population: Type 1 or type 2 diabetes SCr < 2.0mg/dL (PYR-205); SCr >2mg/dL and <3.5mg/dL (
Slide 25: PYR-210 Phase 2b study in Type 2 Diabetes with Overt Nephropathy
25 PYR-210 – 52 wk Phase 2b study in Type 2 Diabetes with Overt Nephropathy (150mg bd and 300 mg bd) PYR-210 Multi-center, randomized, double-blind, placebo-controlled trial to assess safety, tolerability and biological activity: N = 317 Population: Type 2 diabetes with overt nephropathy Baseline SC
Slide 26: NephroGenex Phase 2 Urinary TGFb Analysis
1 PYR-206 recruited mild to moderate DN patients with a PCR value of >300mg/g and dosed 50mg BID for 6 months 2 PYR-205/207 recruited moderate to advanced DN patients with a PCR value of >300mg/g and dosed 50mg BID for 2 weeks, 100 mg BID for 2 weeks and 250 mg BID for 20 weeks 3 PYR-210 recruited a
Slide 27: Pyridorin Safety Profile: PYR-210
Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300mg BID Pyridorin Safety Profile: PYR-210 27 Most Reported Adverse Events Most Reported Serious Adverse Events No meaningful differences between groups in
Slide 28: Primary and Key Secondary Endpoints
Primary Endpoints: Evaluate Pyridorin 300mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: A serum creatinine (SCr) increase of >50% fro
Slide 29: Serum Creatinine and eGFR Definitions and Comparison
Definition Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Comparison
Slide 30: NephroGenex Competitive Environment
NephroGenex Competitive Environment 30 Compound Company Phase MoA Expected Launch Year atrasentan AbbVie 3 Endothelin A receptor antagonist 2016 CCX140-B Chemo Centryx 3 CCR2 Antagonist 2018 canagliflozin Johnson & Johnson 3 Sodium/glucose co-transporter 2 inhibitor Est. 2020 (Ph 3 results are expec
Slide 31: NephroGenex Competitive Environment (cont'd)
NephroGenex Competitive Environment (cont’d) 31 Compound Company Phase MoA Expected Launch Year BMS-813160 Bristol-Myers Sqibb 2 Mineralocorticoid antagonist N/A PBI-4050 ProMetic Life Sciences 2 Unknown N/A CTP-499 CoNCERT Pharma 2 MCP-1 antagonist 2019 ASP-8232 Astellas 2 CC chemokine receptor 2 a